Objectives-To establish baseline concentrations of plasminogen activators and their inhibitors in normal knee synovial fluids, and to compare them with weli characterised osteoarthritis (OA) and rheumatoid arthritis (RA) knee fluids. Methods-A total of 26 normal subjects, 71 patients with OA, and 17 patients with RA underwent knee aspiration. Patients with OA were subclassified according to presence ofnodal generalised OA (NGOA) and synovial fluid calcium pyrophosphate crystals. Clinical assessment of inflammation (graded 0-6) was undertaken in OA and RA patients. Plasminogen activator (PA), plasminogen activator inhibitor (PAI), and urokinase-type PA receptor (uPAR) antigen concentrations were determined by enzyme linked immunosorbent assay. The species of PAs present were determined by sodium dodecyl sulphatepolyacrylamide gel electrophoresis.
fluids, and to compare them with weli characterised osteoarthritis (OA) and rheumatoid arthritis (RA) knee fluids. Methods-A total of 26 normal subjects, 71 patients with OA, and 17 patients with RA underwent knee aspiration. Patients with OA were subclassified according to presence ofnodal generalised OA (NGOA) and synovial fluid calcium pyrophosphate crystals. Clinical assessment of inflammation (graded 0-6) was undertaken in OA and RA patients. Plasminogen activator (PA), plasminogen activator inhibitor (PAI), and urokinase-type PA receptor (uPAR) antigen concentrations were determined by enzyme linked immunosorbent assay. The species of PAs present were determined by sodium dodecyl sulphatepolyacrylamide gel electrophoresis. Results-Concentrations of all antigens (uPA, tissue-type PA (tPA), uPAR, and PAI-1), were significantly greater in RA than OA; those in OA were significantly greater than normal. The concentrations showed no direct association with clinically assessed inflammation of the knee. In normal fluids, no associations with age were observed. Antigen concentrations (uPA, tPA, and uPAR) in NGOA differed from those in other subclasses of OA, but the species of PA present did not appear to vary between disease groups. The predominant PA appeared to have identity with uPA. Conclusion-Because of the greater concentrations of these antigens in OA compared with normal fluids, OA cannot be used as a surrogate normal control in studies ofthe PA/PAI system. Alteration of the PA/PAI system was confirmed in RA and OA knee fluids, with greater changes evident in RA. The finding of different concentrations of PA antigens in NGOA compared with other OA fluids further supports a different pathogenic mechanism in this subset.
(Ann Rheum Dis 1996; 55: [230] [231] [232] [233] [234] [235] [236] Plasminogen activators (PAs) are serine proteases that convert the zymogen, plasminogen, to plasmin. There are two forms of PA: tissuetype (tPA) and urokinase-type (uPA); they are products of different genes, having different molecular weights and immunological reactivity, and differing in their affinity for fibrin.' 2
The PA system can have both direct and indirect effects on extracellular matrix degradation. Plasminogen activators have a direct role in the degradation of extracellular matrix glycoproteins,3 and plasmin, formed by activation of plasminogen, can degrade connective tissue components, including proteoglycans. 4 5 The metalloproteases collagenase and stromelysin are also implicated in cartilage degradation,6
and plasmin can transform their latent forms, procollagenase and prostromelysin, into the active forms,7 8 which can then specifically attack the extracellular cartilage matrix.
The activity of uPA and tPA is regulated by specific plasminogen activator inhibitors (PAIs). Both PAI-I and PAI-2 form stable complexes with tPA and uPA. PAI-I is the main PAI in plasma9 and is also bound to extracellular matrix, where it may regulate matrix breakdown. ' Standing anteroposterior and lateral 300 plain radiographs taken at the time of, or within six months of, aspiration were obtained in all OA patients. Joint space narrowing and osteophyte formation were each scored 0-3 in each of the three compartments, using an atlas.23 A summated score (0-18) was calculated for each knee.
Patients with rheumatoid arthritis (RA)
fulfilling American College of Rheumatology criteria24 and with symptomatic knee involvement were also studied. Synovial fluid was also obtained from two patients during episodes of acute pseudogout (self limiting florid acute synovitis with calcium pyrophosphate crystals demonstrated in synovial fluid, resolving completely within three weeks).
In all patients (OA subsets, RA, pseudogout) clinical inflammation of the knee at the time of aspiration was designated active (score 4-6) or inactive (score 0-2) using a summated score of six clinical parameters.25 SAMPLE 
COLTEJCTION
Knees were aspirated to apparent dryness via a medial approach, and the aspirated volume recorded. A small sample was examined for the presence of crystals and the remainder collected into sterile plastic containers on ice, centrifuged at 2500 g for 15 Imubind ELISA kits (American Diagnostica Inc) were used. Absorbances were read on a Dynatech MR5000 plate reader, using BioLinx software. The kits detected active, inactive, and complexed forms of each antigen. The lower limits of detection were 1 ng/ml PAI-1, 50 pg/ml PAI-2, 10 pg/ml uPA, and 0 1 ng/ml uPAR.
MEASUREMENT OF tPA ANTIGEN BY ELISA
A Chromogenix Coaliza kit (supplied by Quadratech) was used. Absorbances were read on a Dynatech MR5000 plate reader, using BioLinx software. The lower limit of detection of the assay was 0 5 ng/ml tPA. MOLECULAR Patients with RA had significantly greater tPA concentrations (median 3 94 ng/ml) than those with OA (median 1-63 ng/ml) and normal subjects (median 128 ng/ml) (p < 0-001), and the concentration in those with OA was significantly greater than that in normal subjects (p < 0-001) (fig 2A) . The samples from patients with pseudogout had concentrations of tPA similar to those in patients with RA (2-35 ng/ml and 4-76 ng/ml). Concentrations of tPA in patients with NGOA were significantly smaller than those in patients with OA (p<0 l001) (fig2B). The concentration of uPAR was significantly greater in patients with RA (median 14-2 ng/ml) than in those with OA (median 4-33 ng/ml) and normal subjects (median 095 ng/ml) (p<OOO 01), and the concentration in patients with OA was significantly greater than that in normal subjects (p < 0001) ( fig 3A) . The those with OA (median 65-84 ng/ml) and normal subjects (median 27-8 ng/ml) (p < 0-01), and those with OA had significantly greater PAI-1 concentrations than normal subjects (p < 0-001) (fig 4) . Samples from patients with pseudogout had PAI-I concentrations similar to those with RA (68-59 ng/ml and 186-52 ng/ml). None of the parameters measured showed a significant correlation with age in normal subjects. and 98 000 appeared on both plasminogen containing and control gels. These enzymes would appear not to be PAs, and their identity remains uncertain; however, they are probably not metalloproteases, because development of the bands could not be inhibited by 1 mmol/l EDTA. Discussion This is the first study to examine PA and PAI parameters, including uPA receptor concentration, in normal human synovial fluid, and to determine the effect of age on these parameters. It is also the first study to investigate possible differences in concentrations of PA/PAI antigens in OA subsets. As a group, the normal subjects were younger than the OA and RA patients. However, no correlation between PA/PAI parameters and age was seen within the broad range of the normal group, so age alone is unlikely to account for the differences observed between the disease groups.
Differences in antigen concentrations between RA patients, OA patients (including subclasses), and normal subjects were consistent. Concentrations in synovial fluid from RA patients were significantly greater than those in OA, and those in synovial fluid from OA patients were significantly greater than those in normal synovial fluid. tPA antigen concentrations in all groups were within the normal Figure 5 Electrophoretic separation ofplasminogen activator species present in synovialfluidfrom patients in different disease groups, on sodium dodecyl sulphate-polyacrylamide gel containing plasminogen and casein. LANE 1: prestained molecular weight markers; LANE 2: urokinase-type plasminogen activator (uPA) standard (high molecular weight) at a concentration of 6 25 U/ml (approximately 78 ng/ml); LANE 3: tissue-type plasminogen activator (tPA) standard (Bowes melanoma, two chain) at a concentration of 6-25 U/ml (approximately 9-5 ng/ml); LANE 4: pseudogout synovialfluid (estimated uPA = 1 48 ng/ml; tPA = 2-35 ng/ml); LANE 5: normal synovialfluid (estimated uPA not measured; tPA = 1 61 ng/ml); LANE 6: RA synovialfluid (estimated uPA = 3 12 ng/ml; tPA 3-73 ng/ml); LANE 7: NGOA synovialfluid (estimated uPA = 1 01 ng/ml; tPA = 1 68 ng/ml); LANE 8: OA synovialfluid (PA estimations not done).
plasma range of 1-12 ng/ml. This supports previous reports of tPA in very small concentrations in synovial fluid, mainly from patients with RA.20 22 27 Cytokine stimulated chondrocytes and endothelial cells are potential sources of tPA in these joints.2829 uPA has been identified as the predominant synovial fluid PA in joint disease.20 22 30 In our study, concentrations of uPA found in OA and RA joints were greater than the normal plasma values of <1 ng/ml, agreeing with previous findings.22 27 30 This suggests that cells within the joint, both resident and inflammatory, may be a source of uPA. uPA is a product of chondrocytes, synovial cells, monocytes, and polymorphonuclear leucocytes;28 31-3 greater concentrations of uPA in RA may thus reflect an increase in inflammatory cells in the joint and increased cellular activation by cytokines.2232
In plasma, uPAR concentrations are less than 0-1 ng/ml.34 Concentrations in synovial fluid are greater than this, in both normal and diseased joints. Shedding of uPARs may represent a mechanism of control of uPA activity, the soluble receptors competing with cell surface receptors for uPA binding, and thus limiting cell surface plasminogen activation. Increased concentrations of cytokines such as tumour necrosis factor in inflamed joints may increase expression and, perhaps, shedding of receptors. 17 PAI-I concentrations remained in the normal plasma range of 4-43 ng/ml in normal synovial fluid, but were increased in diseased joints. Brommer et a130 found that PAI-I concentrations in synovial fluid from patients with RA were greater than in those in normal plasma, but Saxne et a122 found concentrations in synovial fluid from patients with RA and OA to be within the normal plasma range. PAI-I can be produced by a number of cell types in the joint.2 11 12 Increased concentrations in RA may be the result of increased cytokine concentrations.32 However, cytokines may have differential effects on PAI-1 production in different cell types: for example, IL-I increases PAI-I in endothelial cells, but decreases it in chondrocytes and synovial cells." 12 35 Such effects may give rise to variability in PAI-1 concentrations in different patients.
PAI-2 was undetectable in normal synovial fluid and concentrations in OA were close to the limit of detection of the assay; however, it was detected in all synovial fluid samples from RA patients. This is in agreement with the findings of other workers. All antigen concentrations were increased in parallel, that of no one antigen varying in isolation. This would suggest an upregulation of the entire PA/PAI system. As PA concentrations increased, PAI concentrations also increased, perhaps reflecting a mechanism to neutralise any increased enzyme activity. However, there may still be an increase in the direct and indirect effects that the PA system has on extracellular matrix degradation. This, in thin, could affect the pathophysiology of RA and OA.
The presence of tPA was difficult to demonstrate in our study. tPA activity on the gels may have been masked by the doublet banding that occurred at Mr = 91-98 000 in both control and plasminogen containing gels. Alternatively, this doublet may represent tPA, as other workers have shown that tPA from synovial fluid runs at Mr= 90 000-possibly the result of association with other proteins in synovial fluid.2' 36 The occurrence of a similar doublet in the control gel could be the result of activation of plasminogen, derived from synovial fluid, which runs close to tPA on the gel.36 However, spiking of synovial fluid with tPA did not produce additional bands of lysis, perhaps suggesting degradation of tPA by other proteolytic enzymes in synovial fluid. Combination of tPA with PAIs would have produced additional bands of lysis, M, = 100 000 corresponding to enzyme-inhibitor complexes, as described by Levin.29 The identity of lysis bands could be confirmed by immunoprecipitation of samples before electrophoresis, using antibodies to tPA or uPA.
Our findings comparing concentrations of PAs and PAIs in synovial fluid from patients with RA and OA are broadly in agreement with those of other workers." 27 30 However, we were also able to compare these values with those in normal synovial fluid, and to measure uPAR concentrations. The increased concentrations of PA/PAM parameters in OA compared with normal indicate that it is not valid to use OA as a surrogate control in this type of study. Our data also confirm that alterations in the PA/PAI system occur in both OA and RA, and these may contribute to the pathophysiology of these diseases.
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